On Thursday, BTIG reaffirmed its Buy rating and $135.00 price target for Abbott Laboratories (NYSE:ABT) stock, which trades on the New York Stock Exchange under the ticker NYSE:ABT. The endorsement follows a recent event in which BTIG analysts met with Abbott's Investor Relations team.
During the Midwest MedTech Bus Tour, BTIG hosted a dinner with Abbott executives, including Vice President Michael Comilla, Senior Director Ryan Aliff, Division VP Tamika LeBean, and Senior Finance Manager Elsa Saavedra. The gathering provided an opportunity for in-depth discussions about the company's performance and prospects.
BTIG's analysis highlighted Abbott's diversified portfolio and its presence in high-growth sectors of the medical technology industry, particularly in Cardiac and Diabetes care. The firm noted Abbott's established leadership positions and strong competitive advantages, also known as moats, in these areas.
The analyst from BTIG expressed a bullish stance on Abbott's future, pointing to the company's upcoming product launches and market expansions. These strategic moves are expected to support sustained sales and earnings growth in both the near and medium-term.
Abbott Laboratories is recognized for its high single-digit to low double-digit organic revenue growth and margin expansion. BTIG's position suggests confidence in the company's ability to continue capitalizing on its strengths within the medical technology space.
In other recent news, Abbott Laboratories has announced a global partnership with Medtronic (NYSE:MDT) to develop a continuous glucose monitoring (CGM) system.
The collaboration aims to integrate Abbott's FreeStyle Libre technology with Medtronic's automated insulin delivery and smart insulin pen systems.
This partnership is expected to benefit over 11 million people worldwide who manage their Type 1 or Type 2 diabetes with multiple daily injections of rapid-acting insulin.
Furthermore, Abbott Laboratories has faced legal challenges recently, with nearly 1,000 lawsuits filed against the company and British firm Reckitt Benckiser (LON:RKT).
The lawsuits allege that the companies failed to adequately warn healthcare providers of increased disease risks when using their infant formula.
On the financial side, Abbott reported robust earnings and revenue for the second quarter, with earnings per share (EPS) of $1.14 exceeding expectations. The company's revenues of $10.38 billion were primarily driven by the Medical Devices segment.
In response to these strong results, Abbott's full-year revenue guidance has been updated to an organic growth range of 9.5%-10%, and its EPS guidance has been raised to $4.61-$4.71 from the previous $4.55-$4.70 range.
Analysts from UBS, Evercore ISI, Citi, and TD Cowen have maintained positive outlooks on Abbott. In terms of product development, Abbott received FDA clearance for two new over-the-counter continuous glucose monitoring systems, Lingo and Libre Rio. These are the recent developments for Abbott Laboratories.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.